Difference between revisions of "Comment Resolutions"
Jump to navigation
Jump to search
m |
|||
(69 intermediate revisions by 3 users not shown) | |||
Line 1: | Line 1: | ||
− | Comments received during Public Comment, Technical Confirmation, or during a Profile ballot, are reviewed by the originating Biomarker Committee. | + | Comments received during Public Comment, Clinically Feasible (formerly Technical) Confirmation, or during a Profile ballot, are reviewed by the originating Biomarker Committee. |
Per the [[Process#Profile_Creation_Process|QIBA Process]], committees record how each '''[[Public Comment Process|collected comment was resolved]]''' and those resolutions are posted here. | Per the [[Process#Profile_Creation_Process|QIBA Process]], committees record how each '''[[Public Comment Process|collected comment was resolved]]''' and those resolutions are posted here. | ||
Line 5: | Line 5: | ||
{| style="width:100%" border="1" cellpadding="3" | {| style="width:100%" border="1" cellpadding="3" | ||
− | ! Document | + | ! Profile Document |
! Feedback Type | ! Feedback Type | ||
! Feedback Closed | ! Feedback Closed | ||
Line 12: | Line 12: | ||
| colspan="4" align="center" style="background:#dddddd" | '''CT Profiles''' | | colspan="4" align="center" style="background:#dddddd" | '''CT Profiles''' | ||
|- | |- | ||
− | | [[Media: | + | | [[Media:QIBA CT Vol LungNoduleAssessmentInCTScreening v5-2-16b.docx| CT Small Lung Nodule Screening 2016-06-01]] |
| Public Comment | | Public Comment | ||
− | | | + | | 2016.09 |
− | | [[Media: | + | | [[Media:2018-06-15 v9 QIBA SLN CommentsAndResolutions.xlsx|Public Comment Resolutions 2018-06-15]] |
|- | |- | ||
− | | [[Media: | + | | [[Media:QIBA CTVol TumorVolumeChangeProfile Consensus-20161121b.pdf| CT Tumor Volumetry for Advanced Disease 2016-11-21b]] |
| Technical Confirmation | | Technical Confirmation | ||
| 2017.02 | | 2017.02 | ||
− | | [https://docs.google.com/spreadsheets/d/1cyz0frvELb6Tq1EHjpHxnvjeUxotExnJ3OrKPdIa30U/edit?usp=sharing Technical Confirmation | + | | [https://docs.google.com/spreadsheets/d/1cyz0frvELb6Tq1EHjpHxnvjeUxotExnJ3OrKPdIa30U/edit?usp=sharing Technical Confirmation Resolutions 2018-02-25] |
+ | |- | ||
+ | | [[Media:QIBA CTA Profile as of 2020-March-10.pdf| CT Atherosclerosis 2020-03-10]] | ||
+ | | Public Comment | ||
+ | | 2019.06.03 | ||
+ | | [[Media:QIBA CTA Comments all resolved.xlsx| Public Comment Resolutions 2020-03-12]] | ||
+ | |- | ||
+ | | [[Media:Atherosclerosis Biomarkers Profile 2023Mar28.pdf| CT Atherosclerosis 2023-03-28]] | ||
+ | | Clinically Feasible | ||
+ | | 2023.03.07 | ||
+ | | [[Media:CTA Profile Clinically Feasible Comment Resolutions.2023Mar28.pdf|Clinically Feasible Comment Resolutions 2023-03-28]] | ||
|- | |- | ||
− | | [[Media: | + | | [[Media:QIBA CT Lung Density Profile 090420-clean.pdf| CT Lung Density 2020-09-04]] |
| Public Comment | | Public Comment | ||
− | | | + | | 2019.10.16 |
− | | ''' | + | |[[Media:QIBA Lung Density Comments resolved.xlsx| Public Comment Resolutions 2020-09-04]] |
+ | |- | ||
+ | |[[Media:QIBA CT Vol SmallLungNoduleAssessmentInCTScreening 2018.11.18-clean-3.pdf|CT Small Lung Nodule Screening 2018-11-18]] | ||
+ | | Technical Confirmation | ||
+ | | 2020.04 | ||
+ | |'''* Resolving Feedback''' | ||
|- | |- | ||
| colspan="4" align="center" style="background:#dddddd" | '''MR Profiles''' | | colspan="4" align="center" style="background:#dddddd" | '''MR Profiles''' | ||
|- | |- | ||
− | | [[Media: | + | | [[Media:Draft-MRE-QIBAProfile-2017-07-28 clean.pdf| MR Elastography 2017-08-15]] |
+ | | Public Comment | ||
+ | | 2017.09.15 | ||
+ | | [[Media:MRE Profile Public Comments 2018 02 08.pdf| Public comment Resolutions]] | ||
+ | |- | ||
+ | | [[Media:QIBA fMRI Profile 1 PC-rev1.pdf| fMRI Sensorimotor 2017-06-19]] | ||
+ | | Public Comment | ||
+ | | 2017.12.31 | ||
+ | | '''Resolving Feedback''' | ||
+ | |- | ||
+ | | [[Media:QIBADWIProfile as of 2019-Feb-05.pdf| MR DWI 2019-02-05]] | ||
| Public Comment #2 | | Public Comment #2 | ||
| 2019.04.05 | | 2019.04.05 | ||
| [[Media:QIBA DWI Profile-Public Comment--2 Resolutions.pdf| Public Comment Resolutions]] | | [[Media:QIBA DWI Profile-Public Comment--2 Resolutions.pdf| Public Comment Resolutions]] | ||
|- | |- | ||
− | | [[Media: | + | | [[Media:QIBA DSC-MRI Stage1 Profile.pdf|MR Dynamic Susceptibility Contrast (DSC-MRI) 2020-01-29]] |
| Public Comment | | Public Comment | ||
− | | | + | | 2020.05.15 |
− | | | + | | [[Media:QIBA DSC-MRI Public Comment Resolutions v2020Oct.9.pdf| Public Comment Resolutions]] |
|- | |- | ||
− | | [[Media: | + | | [[Media:QIBA Profile MSK-Cartilage-Stage1 Profile.pdf|MR MSK cartilage compositional biomarkers (T1ρ,T2) 2020-05-18]] |
| Public Comment | | Public Comment | ||
− | | | + | | 2020.10.29 |
− | | | + | | [[Media:QIBA MSK BC Public Comment Resolutions.pdf| Public Comment Resolutions]] |
|- | |- | ||
− | | [[Media: | + | | [[Media:QIBA DCE-MRI Profile-Stage 1-Public Comment.pdf|MR DCE-MRI Quantification (DCEMRI-Q) 2020-10-12]] |
| Public Comment | | Public Comment | ||
− | | | + | | 2021.03.10 |
− | | ''' | + | | '''Resolving Feedback''' |
+ | |- | ||
+ | | [[Media:MRE-QIBAProfile-2022-02-14-TECHNICALLY-CONFIRMED.pdf| MR Elastography of the Liver 2022-02-14]] | ||
+ | | Technical Confirmation | ||
+ | | 2021.12.16 | ||
+ | | [[Media:QIBATechnicalConfirmationResolutions MRE.pdf| Technical Confirmation Resolutions 2022-02-14]] | ||
+ | |- | ||
+ | | [[Media:QIBA DWIProfile Stage3 15Dec2022 v3.pdf| MR Diffusion-Weighted Imaging (DWI) of the Apparent Diffusion Coefficient (ADC) 2022-12-15]] | ||
+ | | Clinically Feasible | ||
+ | | 2022.12.15 | ||
+ | | [[Media:QIBA DWI-MR Clinical Feasibility Resolutions.pdf| Clinically Feasible Resolutions 2022-12-15]] | ||
|- | |- | ||
| colspan="4" align="center" style="background:#dddddd" | '''PET/NM Profiles''' | | colspan="4" align="center" style="background:#dddddd" | '''PET/NM Profiles''' | ||
|- | |- | ||
− | | [[Media: | + | | SPECT Ioflupane in Neurodegenerative Disease v1.1 |
+ | | Public Comment | ||
+ | | 2016.12.31 | ||
+ | | [[Media:SPECT Profile Response to Public Comments.v2017 06 06.xlsx| Public Comment Resolutions 2017-06-06]] | ||
+ | |- | ||
+ | | [[Media:QIBA AmyloidPET 15June2017.pdf| PET Amyloid 2019-06-15]] | ||
+ | | Technical Confirmation | ||
+ | | 2021 | ||
+ | | [[Media:QIBA PET Amyloid Profile changes.pdf| Technical Confirmation Resolutions, 2022-04-15]] | ||
+ | |- | ||
+ | | [[Media:QIBA AmyloidPET 15June2017.pdf| PET Amyloid 2017-06-15]] | ||
+ | |Public Comment | ||
+ | |2017.09.15 | ||
+ | |[[Media:QIBA PET Amyloid Comments all resolved.xlsx| Public Comment Resolutions 2018-05-02]] | ||
+ | |- | ||
+ | | [[Media:002.QIBA SPECT Ioflupane Profile v2.0.2019 10 15.pdf| SPECT Ioflupane in Neurodegenerative Disease v2.0, 2019-10-15]] | ||
+ | | Public Comment | ||
+ | | n/a | ||
+ | | v2.0 is an update of v1.0 without additional public comment | ||
+ | |- | ||
+ | |[[Media:QIBA 99mTC SPECT 2020-05-12.pdf| SPECT 99mTC 2020-05-12]] | ||
+ | | Public Comment | ||
+ | | 2020.02.03 | ||
+ | |[[Media:QIBA 99mTC SPECT Comments 2020-08-11-final.xlsx| Public Comment Resolutions 2020-08-11]] | ||
+ | |- | ||
+ | | colspan="4" align="center" style="background:#dddddd" | '''Ultrasound Profiles''' | ||
+ | |- | ||
+ | | [[Media:QIBA US SWS Profile 10.21.19.pdf|US Shear Wave Speed for Liver Fibrosis 2019-10-21]] | ||
| Public Comment | | Public Comment | ||
− | | | + | | 2019.12.18 |
− | | | + | | [[Media:QIBA US SWS Comments 2021-02-06-final.xlsx| Public Comment Resolutions 2021-02-06]] |
+ | |- | ||
+ | | [[Media:QIBA US SWS Profile 2023-02-07.pdf|US Shear Wave Speed for Liver Fibrosis 2023-02-07]] | ||
+ | | Clinically Feasible | ||
+ | | 2023.02.07 | ||
+ | | [[Media:QIBA US SWS Comments 2023-02-20-v2.xlsx| Clinically Feasible Comment Resolutions 2023-02-20]] | ||
|- | |- | ||
+ | |} |
Latest revision as of 17:25, 4 April 2023
Comments received during Public Comment, Clinically Feasible (formerly Technical) Confirmation, or during a Profile ballot, are reviewed by the originating Biomarker Committee.
Per the QIBA Process, committees record how each collected comment was resolved and those resolutions are posted here.